Treatment protocols for small and large bowel cancer
- Authors
- Tim Brenner, PharmD, BCOP
Tim Brenner, PharmD, BCOP
- Clinical Pharmacy Specialist
- UPMC Cancer Centers
- Shrina Duggal, PharmD, BCOP
Shrina Duggal, PharmD, BCOP
- Clinical Pharmacy Specialist
- UPMC Cancer Centers
- Jim Natale, PharmD, BCOP
Jim Natale, PharmD, BCOP
- Clinical Pharmacy Specialist
- UPMC Cancer Centers
- Scott M Wirth, PharmD, BCOP
Scott M Wirth, PharmD, BCOP
- Clinical Pharmacy Specialist
- UPMC Cancer Centers
- Section Editor
- John W Mucenski, PharmD
John W Mucenski, PharmD
- Section Editor — Chemotherapy Regimens
- Director
- Pharmacy Operations
- UPMC Cancer Centers
- Deputy Editor
- Diane MF Savarese, MD
Diane MF Savarese, MD
- Senior Deputy Editor — UpToDate
- Deputy Editor — Oncology and Palliative Care
- Clinical Instructor of Medicine
- Harvard Medical School
INTRODUCTION
The following material represents a subset of chemotherapy regimens that are used for the treatment of patients with small bowel and colorectal cancer, both in the adjuvant setting and for advanced disease. This is not an exhaustive list; it includes regimens that are considered by the authors and editors to be commonly used and important for the care of patients with bowel cancer. Additional regimens may be added over time, particularly as treatment for colorectal cancer evolves.
This topic review is intended to provide only a listing of chemotherapy regimens. It does not address the appropriate context for use of these regimens in the care of patients with colorectal cancer. Clinicians should refer to the individual disease-oriented topic reviews that discuss the use of these protocols in appropriate clinical situations:
●(See "Systemic chemotherapy for metastatic colorectal cancer: General principles".)
●(See "Systemic chemotherapy for nonoperable metastatic colorectal cancer: Treatment recommendations".)
Subscribers log in here
To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:Literature review current through: Jun 2017. | This topic last updated: Oct 27, 2016.The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.Topic Outline- INTRODUCTION
- REGIMENS
- Chemotherapy
- - Short-term infusional fluorouracil and leucovorin (modified de Gramont schedule)
- - Weekly bolus fluorouracil plus high-dose leucovorin (Roswell Park Memorial Institute [RPMI] regimen)
- - Capecitabine plus bevacizumab
- - Modified FOLFOX6 (fluorouracil plus leucovorin and oxaliplatin)
- - Modified FOLFOX6 plus bevacizumab
- - Modified FOLFOX7
- - Modified FOLFOX7 plus bevacizumab
- - Capecitabine plus oxaliplatin for small intestinal adenocarcinoma
- - Capecitabine plus oxaliplatin (XELOX, CAPOX) for colorectal cancer
- - XELOX/CAPOX plus bevacizumab for colorectal cancer
- - FOLFIRI (fluorouracil plus leucovorin and irinotecan)
- - FOLFIRI plus bevacizumab
- - FOLFOXIRI (fluorouracil plus leucovorin, oxaliplatin, and irinotecan)
- - Weekly single agent cetuximab
- - Single agent panitumumab
- - Cetuximab plus irinotecan
- - FOLFIRI plus cetuximab
- - FOLFIRI plus panitumumab
- Concomitant chemoradiotherapy for rectal cancer
- - Concomitant chemoradiotherapy with capecitabine for rectal cancer in both the adjuvant and neoadjuvant setting
- - Concomitant chemoradiotherapy with infusional fluorouracil for rectal cancer in both the adjuvant and neoadjuvant setting
GRAPHICS